Ketamine effects on brain function — Simultaneous fMRI/EEG during a visual oddball task

Musso, Francesco; Brinkmeyer, Jürgen; Ecker, Daniel; London, Markus K.; Thieme, Giesela; Warbrick, Tracy; Wittsack, Hans‐Jörg; Saleh, Andreas; Greb, Wolfgang; Boer, P. de; Winterer, Georg

doi:10.1016/j.neuroimage.2011.06.045

Cited by 73 publications

(67 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is consistent with previous studies in the auditory and visual domains (47)(48)(49)(50)(51)(52)(53)86) although we observed a strong effect only in the encoding phase with the retrieval significance reduced to a trend. We also found a trend for correlation between P300 and cognitive performance under ketamine for both encoding and retrieval conditions.…”

Section: P300supporting

confidence: 93%

“…We also found a trend for correlation between P300 and cognitive performance under ketamine for both encoding and retrieval conditions. A study using EEG space source localization and fMRI showed that ketamine extinguished primarily the parietal locus of the frontoparietal network generating P300 (51). This is in agreement with other studies showing that ketamine preferentially attenuates the parietally generated P300b component,…”

Section: P300supporting

confidence: 86%

“…Studies so far have focused on auditory oddball paradigms and reported reductions in P300 as well as a marker of automatic WM update, mismatch negativity (47)(48)(49)(50). Visual experiments have focused exclusively on later ERP components, reporting an attenuation of the P300 component (51)(52)(53).…”

Section: Q4mentioning

confidence: 99%

See 2 more Smart Citations

Effects of Acute Ketamine Infusion on Visual Working Memory: Event-Related Potentials

Koychev

Deakin

El‐Deredy

et al. 2017

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging

View full text Add to dashboard Cite

This is the accepted version of the paper.This version of the publication may differ from the final published version. ABSTRACT BACKGROUND: Working memory (WM) deficits are a core feature of schizophrenia. Electrophysiological studies suggest that impaired early visual processing may contribute to impaired WM in the visual domain. Abnormal N-methyl-D-aspartate (NMDA) receptor function has been implicated both in WM and in early visual processing deficits in schizophrenia. We investigated whether ketamine, a noncompetitive NMDA antagonist, would replicate in healthy volunteers the WM performance and early visual processing abnormalities we and others have reported in patients with schizophrenia. METHODS: Forty-four healthy volunteers were randomly assigned to receive intravenous ketamine or placebo. During infusion, the effects of ketamine were recorded using standardized psychiatric scales. Visual evoked potentials (P100 and P300 components) were recorded during performance of a delayed matching to sample task. RESULTS: Ketamine induced mild psychosis-like symptoms and impaired WM performance. It also significantly increased the P100 amplitude, while P300 amplitude decreased in a load-dependent manner. Amplitudes of P100 during retrieval correlated with cognitive performance only in the placebo group. CONCLUSIONS: We confirmed previous studies showing that ketamine reproduces the impairment of WM performance and smaller P300 amplitudes observed in schizophrenia. However, ketamine increased visual P100 amplitude in contrast to our observation of reduced P100 amplitudes in established schizophrenia. The effects of ketamine on WM and P300 are likely to involve impaired NMDA function, as these receptors are implicated in changes of synaptic strength underlying associative learning and memory. Increased P100 amplitude may reflect the secondary disinhibition of cortical glutamate release that occurs after NMDA blockade. Permanent repository link

show abstract

Section: P300supporting

confidence: 93%

Section: P300supporting

confidence: 86%

See 1 more Smart Citation

Effects of Acute Ketamine Infusion on Visual Working Memory: Event-Related Potentials

Koychev

Deakin

El‐Deredy

et al. 2017

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging

View full text Add to dashboard Cite

show abstract

“…41 The scale was previously shown to be sensitive to the psychological effects of NMDAR antagonists in humans 42 and was conducted after both EEG recording sessions.…”

Section: Psychometric Assessmentmentioning

confidence: 99%

“…63 Accordingly, the PANSS has been used in several recent studies investigating ketamine-induced schizophrenia-like symptoms in healthy volunteers. 42,64,65 Fig. 6: Low-resolution brain electromagnetic tomography (LORETA) results comparing (A) early and (B) late mismatch negativity (MMN) of placebo and ketamine for the frequency deviant.…”

Section: Limitationsmentioning

confidence: 99%

Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced mismatch negativity alterations in healthy male humans

Thiebes

Leicht

Ćurić

et al. 2017

JPN

View full text Add to dashboard Cite

Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia

et al. 2020

View full text Add to dashboard Cite

IMPORTANCE Ketamine hydrochloride is increasingly used to treat depression and other psychiatric disorders but can induce schizophrenia-like or psychotomimetic symptoms. Despite this risk, the consistency and magnitude of symptoms induced by ketamine or what factors are associated with these symptoms remain unknown. OBJECTIVE To conduct a meta-analysis of the psychopathological outcomes associated with ketamine in healthy volunteers and patients with schizophrenia and the experimental factors associated with these outcomes. DATA SOURCES MEDLINE, Embase, and PsychINFO databases were searched for withinparticipant, placebo-controlled studies reporting symptoms using the Brief Psychiatric Rating Scale (BPRS) or the Positive and Negative Syndrome Scale (PANSS) in response to an acute ketamine challenge in healthy participants or patients with schizophrenia. STUDY SELECTION Of 8464 citations retrieved, 36 studies involving healthy participants were included. Inclusion criteria were studies (1) including healthy participants; (2) reporting symptoms occurring in response to acute administration of subanesthetic doses of ketamine (racemic ketamine, s-ketamine, r-ketamine) intravenously; (3) containing a placebo condition with a within-subject, crossover design; (4) measuring total positive or negative symptoms using BPRS or PANSS; and (5) providing data allowing the estimation of the mean difference and deviation between the ketamine and placebo condition. DATA EXTRACTION AND SYNTHESIS Two independent investigators extracted study-level data for a random-effects meta-analysis. Total, positive, and negative BPRS and PANSS scores were extracted. Subgroup analyses were conducted examining the effects of blinding status, ketamine preparation, infusion method, and time between ketamine and placebo conditions. The Metaanalysis of Observational Studies in Epidemiology (MOOSE) and Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed. MAIN OUTCOMES AND MEASURES Standardized mean differences (SMDs) were used as effect sizes for individual studies. Standardized mean differences between ketamine and placebo conditions were calculated for total, positive, and negative BPRS and PANSS scores. RESULTS The overall sample included 725 healthy volunteers (mean [SD] age, 28.3 [3.6] years; 533 [73.6%] male) exposed to the ketamine and placebo conditions. Racemic ketamine or S-ketamine was associated with a statistically significant increase in transient psychopathology in healthy (continued) Key Points Question What psychopathological outcomes are associated with ketamine hydrochloride in healthy volunteers and patients with schizophrenia, and what factors are associated with these outcomes? Findings This meta-analysis of 36 studies, including 725 unique healthy participants, found that the acute administration of ketamine relative to placebo was associated with a meaningful increase in positive and negative symptoms of psychosis in healthy volunteers and patients with schizophrenia. This assoc...

show abstract

Ketamine effects on brain function — Simultaneous fMRI/EEG during a visual oddball task

Cited by 73 publications

References 104 publications

Effects of Acute Ketamine Infusion on Visual Working Memory: Event-Related Potentials

Effects of Acute Ketamine Infusion on Visual Working Memory: Event-Related Potentials

Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced mismatch negativity alterations in healthy male humans

Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia

Contact Info

Product

Resources

About